F-1/A: Living Homeopathy Files IPO for Nasdaq Listing

Living Homeopathy International Ltd., a Hong Kong-based homeopathy service provider, filed an amendment for its initial public offering of 1,250,000 Class A Ordinary Shares on the Nasdaq Capital Market, with an estimated price range of $4.0 to $6.0 per share.

Summary

• Living Homeopathy International Ltd. is offering 1,250,000 Class A Ordinary Shares in its initial public offering, with an estimated price between $4.0 and $6.0 per share.
• The company is a Hong Kong-based homeopathy service provider, ranked first in the Hong Kong homeopathy market with approximately 35.8% market share in terms of product sales revenue in 2024.
• Net proceeds from the offering are estimated at $3.84 million (or $5.00 million if the over-allotment option is fully exercised), to be used for advertising planning (40%), market and product development/marketing (30%), and working capital/general corporate purposes (30%).
• Total net revenue for the year ended March 31, 2025, decreased slightly by 1.0% to $8,422,639 from $8,510,216 in 2024.
• Net income increased by 7.8% to $812,130 for the year ended March 31, 2025, compared to $753,429 in 2024.
• Gross profit increased by $42,436 to $6,423,394 in 2025, with gross margin improving from 75.0% to 76.3%.
• Operating expenses increased by 6.9% to $5,833,144 in 2025, primarily due to significant increases in legal and professional fees (4,444.2% increase to $270,653) and other general and administrative expenses (86.8% increase to $686,582), largely driven by IPO-related costs and event fees.
• The company operates a dual-class share structure, with Class B Ordinary Shares carrying 15 votes per share, and Class A Ordinary Shares carrying 1 vote per share.
• Mr. Ka Lun To, Chairman and CEO, will retain approximately 49.43% of total voting power post-offering, assuming no over-allotment exercise, through his holding company.

Sentiment

Score: 7

Explanation: The company is undertaking a significant growth step with its IPO, backed by a leading market position in Hong Kong's growing homeopathy sector and positive net income growth. While operating income was impacted by IPO-related expenses, these are non-recurring. The regulatory risks associated with Hong Kong/PRC are notable but the company has legal opinions supporting its current compliance. The dual-class share structure and lack of dividends are considerations for investors, but the overall strategic direction and market position are favorable.

Positives

• Ranked first in the Hong Kong homeopathy market with approximately 35.8% market share in 2024, indicating strong market influence.
• Diversified product portfolio including homeopathic remedies, co-remedies, classical flower remedies, personal care products, and water filters, catering to a broad customer base.
• Established quality control practices, including supplier certification requirements and regular product testing by Hong Kong STC, with key products eligible for the STC Certified Mark.
• Maintains long-term business relationships (over a decade with most top 5 suppliers), providing stable supply and reducing negotiation costs.
• Experienced management team and a mentor-mentee program with 687 practitioners holding Homeopathy First Aid Certificates, including 71 nutritional therapy practitioners, enhancing service quality and market reach.
• Net income increased by 7.8% to $812,130 in 2025, demonstrating profitability growth.
• Gross profit increased by $42,436 and gross margin improved from 75.0% to 76.3% in 2025, indicating efficient product sourcing and pricing strategies.
• Generated positive cash flow from operating activities of $1,463,328 in 2025, up from $687,495 in 2024.
• The company's auditor, WWC, P.C., is headquartered in California and subject to regular PCAOB inspections, mitigating risks associated with the Holding Foreign Companies Accountable Act (HFCA Act).

Negatives

• Total net revenue decreased by 1.0% to $8,422,639 in 2025, primarily due to a 55.1% decrease in sales of water filters and related products.
• Significant increase in legal and professional fees (4,444.2% to $270,653) and other general and administrative expenses (86.8% to $686,582) in 2025, largely due to IPO-related costs and event fees, impacting operating income.
• Operating income decreased by 36.3% to $590,250 in 2025, primarily due to increased operating expenses.
• The company does not have written contracts with any of its suppliers, which reduces procurement predictability and could lead to order cancellations or modifications on short notice without penalty.
• Reliance on a limited number of suppliers, with three suppliers accounting for 37%, 25%, and 21% of total purchases in 2025, creating supplier concentration risk.
• The company does not maintain business interruption or product liability insurance, which could expose it to significant costs and business disruption in case of unforeseen events or claims.
• The company does not anticipate paying cash dividends to U.S. investors in the foreseeable future, meaning returns will rely solely on share price appreciation.

Risks

• Operating in a competitive and rapidly evolving industry, making it difficult to evaluate prospects and manage growth effectively.
• Unfavorable publicity or consumer acceptance of products, including past negative publicity on 'LIVING Colloidal Silver', could reduce sales and damage reputation.
• Heavy regulation of the business and potential for increasingly tightened regulatory requirements and scrutiny in Hong Kong and new markets like mainland China, which could adversely affect business growth and financial results.
• Potential product liability, false marketing, or other consumer claims, leading to substantial liabilities and regulatory penalties.
• Risk of enforcement action if employees or mentor-mentee participants engage in improper marketing or promotion of products, especially given the lack of written agreements with non-employee participants.
• Sustainability of the mentor-mentee program relies on strict compliance with, and effective enforcement of, marketing manuals and relevant laws, including those regulating pyramid schemes.
• Risk of product recalls, leading to significant and unexpected costs and damage to reputation.
• Requirement for substantial additional funding in the future, with no assurance that additional financing will be available on reasonable terms.
• Damage to brand reputation from adverse publicity or product-related litigation.
• Increases in labor costs in Hong Kong and non-compliance with employment and labor protection laws.
• Failure to manage and expand supplier relationships or procure products at favorable terms.
• Dependence on continued efforts of senior management; loss of key executives could severely disrupt business.
• Directors, management, and shareholders may be subject to negative publicity, claims, or legal proceedings.
• Reliance on proprietary information (trade secrets, know-how) without statutory protection in Hong Kong, making enforcement difficult.
• Accusations of infringing intellectual property rights of others.
• Failure to maintain satisfactory performance of information technology systems.
• Improper use, disclosure, or unauthorized access to customer data.
• Potential adverse effects from epidemics, natural disasters, and other catastrophes.
• Directors and officers, along with Class B shareholders, control a significant percentage of total voting power (91.09% post-offering), potentially limiting minority shareholder influence.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to incorporation under Cayman Islands law.
• Uncertainties regarding future approvals from mainland China and Hong Kong authorities for U.S. listing and offering securities, which could significantly hinder operations or render securities worthless.
• Potential for more stringent requirements from the PRC government for sharing business and accounting records with foreign auditing firms, impacting access to U.S. capital markets.
• Difficulty for overseas shareholders and/or regulators to conduct investigations or collect evidence within mainland China.
• Additional costs and procedural obstacles in enforcing foreign judgments or bringing actions in Hong Kong.
• Impact of the Hong Kong currency peg system.
• No prior public market for Class A Ordinary Shares, leading to potential price volatility and illiquidity.
• Risk of delisting under the HFCA Act if the auditor is not subject to PCAOB inspections for two consecutive years, despite the current auditor being U.S.-based.
• Increased costs and management time associated with being a public company, especially after ceasing to qualify as an emerging growth company.
• Potential for extreme stock price volatility unrelated to operating performance due to small capitalization and public float.
• Immediate and substantial dilution for new investors due to the initial public offering price being significantly higher than net tangible book value per share.
• Management discretion in the use of offering proceeds, which may not align with investor expectations.
• Potential classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.

Future Outlook

The company plans to diversify sales channels by developing an online flagship store on Tmall Global to sell brand-name goods to consumers in mainland China, focusing on homeopathic co-remedies. It also intends to promote market regularization and standardization of the homeopathy market in Hong Kong and mainland China by working with regional institutes and medical schools. The company intends to retain all future earnings for business expansion and does not anticipate paying cash dividends to U.S. investors in the foreseeable future.

Management Comments

• Mr. Ka Lun To, our Chairman and Chief Executive Officer, through his holding company, has beneficial ownership and control over 4,680,000 Class A Ordinary Shares and 520,000 Class B Ordinary Shares, representing approximately 52% of our total voting power and immediately after the completion of this offering, Mr. To, through his holding company, will continue to have beneficial ownership and control over 4,680,000 Class A Ordinary Shares and 520,000 Class B Ordinary Shares, representing approximately 49.43% of our total voting power, assuming the underwriters do not exercise their over-allotment option.
• We believe that we may leverage this established market share to enhance the market influence of our brand name to further attract customer attention and increase our sales.
• We believe that our existing resources, including cash generated from operations, will be sufficient to meet our working capital requirement for our current operating and capital expenditure needs and obligations over the next twelve months.

Industry Context

The Traditional and Complementary Medicine (T&CM) market in Hong Kong is experiencing robust growth, expanding from $176 million in 2019 to $309.4 million in 2023 (15.1% CAGR), with projections to reach $1,299.1 million by 2029 (25.3% CAGR from 2024-2028). This growth is driven by increasing health consciousness, cultural acceptance of traditional practices, rising prevalence of chronic diseases, an increasing aging population, and the expansion of product portfolios by key players. The homeopathy market specifically grew from $16.6 million in 2019 to $20 million in 2023 (4.8% CAGR) and is projected to accelerate to a 12.0% CAGR from 2024-2028, reaching $42.9 million by 2029. Living Homeopathy is a key player in this growing market, holding the largest market share in Hong Kong's homeopathy sector.

Comparison to Industry Standards

• Living Homeopathy is ranked first in the Hong Kong homeopathy market by market share (approximately 35.8% in 2024), indicating a leading position among local competitors like HomeoCare HK, Vitality Centre, Integrated Medicine Institute, and Maya Health Institute.
• The company's focus on diversified product offerings and established quality control practices aligns with industry trends emphasizing natural remedies and consumer trust.
• The mentor-mentee program is a unique sales and marketing network that leverages customer participation, potentially differentiating it from competitors relying solely on traditional retail or clinical models.
• The company's expansion into Tmall Global for mainland China sales positions it to capitalize on the broader T&CM market growth drivers, such as increasing demand for naturally sourced products and higher adoption rates of homeopathy in the region.

Management Changes

Corporate Governance

Legal Proceedings

• No current legal proceedings that, in management's opinion, would have a material adverse effect on the business, financial condition, operating results, or cash flows.

Related Party Transactions

• Revenue from sales to Living Homeopathy Limited (Macau), an entity controlled by Mr. To, was $390,842 in 2025 and $368,969 in 2024.
• Cost of revenue from purchases from Living Homeopathy Limited (Macau) was $417,843 in 2025 and $456,773 in 2024.
• Lease expenses paid to Silver Link Limited, an entity controlled by Mr. To, were $184,780 in 2025 and $184,036 in 2024.
• Transfer of land and building from Living HK to Mr. To for $1,962,362 in 2025, which also settled bank borrowings of $2,162,619.
• Constructive dividends of $983,560 recorded in 2025 and cash dividends of $325,078 declared in 2024 to LTO Holdings Ltd., Mr. To's controlling shareholder.
• Amount due to Ms. Hung Chi Ching (shareholder) was $924,241 as of March 31, 2025, for working capital use (interest-free, unsecured, repayable on demand).

Stakeholder Impact

• **Shareholders (New Investors)**: Will experience immediate and substantial dilution of approximately $4.39 per Class A Ordinary Share. Returns will primarily depend on price appreciation as no dividends are anticipated in the foreseeable future. Voting power will be significantly diluted due to the dual-class share structure, with existing insiders retaining substantial control.
• **Shareholders (Existing/Controlling)**: Mr. Ka Lun To and other Class B shareholders will retain significant voting power (approximately 91.09% collectively post-offering), maintaining control over corporate decisions. They have previously waived dividend rights to retain profits within the company.
• **Employees**: The company's success depends on attracting, retaining, and motivating qualified employees. The mentor-mentee program involves employees and offers sales commissions and product discounts. Increased labor costs in Hong Kong could impact profitability.
• **Customers**: The company aims to enhance public awareness of homeopathy and its products through various marketing approaches, including the mentor-mentee program. Product quality control measures are in place to ensure safety and efficacy. Expansion to Tmall Global aims to reach mainland China consumers.
• **Suppliers**: The company relies on a limited number of suppliers and operates without written contracts, which could affect supply continuity and terms. Long-term relationships with major suppliers are a strength, but concentration risk exists.
• **Regulatory Bodies**: The company is subject to various Hong Kong and potentially PRC regulations, including food safety, consumer goods safety, trade descriptions, and anti-pyramid scheme laws. Compliance costs and potential regulatory scrutiny are ongoing concerns, especially with expansion into mainland China.

Next Steps

• Listing Class A Ordinary Shares on the Nasdaq Capital Market under the symbol LHI, contingent on final Nasdaq approval.
• Consummating the initial public offering promptly after the effective date of the registration statement.
• Diversifying sales channels by developing an online flagship store on Tmall Global for mainland China consumers.
• Promoting market regularization and standardization of the homeopathy market in Hong Kong and mainland China.
• Continuing to invest future earnings into the expansion of Hong Kong operating subsidiaries.

Key Dates

Recommendation

Living Homeopathy holds a strong market position in Hong Kong's growing homeopathy sector and has demonstrated profitability. The IPO provides capital for strategic expansion, particularly into mainland China via Tmall Global, which could drive future growth. However, the significant regulatory uncertainties related to operating in Hong Kong and expanding into mainland China, coupled with the dual-class share structure concentrating voting power, present considerable risks. The immediate and substantial dilution for new investors and the absence of anticipated dividends also weigh on the investment case. A 'hold' recommendation is appropriate, suggesting investors monitor how the company navigates these regulatory and market expansion challenges, and how its financial performance evolves post-IPO, before making further investment decisions.

Keywords

Homeopathy, Hong Kong, SEC F-1/A, IPO, Nasdaq Capital Market, Healthcare Products, Personal Care Products, Water Filters, Alternative Medicine, Emerging Growth Company, Dual-Class Shares, Regulatory Risk, China Risk, PCAOB, Financial Performance